Impact of estroprogestin therapies on bone health from adolescence to postmenopause

Read full text
Authors: Guabello Gregorio, Federici Silvia, Carrara Silvia, Ruotolo Elena, Rossi Antonio, Bertini Jacopo, Bonomi Marco, Grandi Giovanni, Sabrina Corbetta
Cited by: 1
References: 107

Abstract

BACKGROUND: Estrogens are fundamental to bone health, exerting life-long effects onbone metabolism. They regulate skeletal growth and maturation during adolescence andmaintain bone remodeling in adulthood. The decline in estrogen levels during perimenopauseand postmenopause leads to bone mass loss. Emerging evidence also supports a role forprogestins in bone metabolism. Several estrogen-progestins formulations are available andwidely used for contraception in fertile women and as hormone replacement therapy (HRT) incases of primary or secondary ovarian insufficiency as well as in physiologic menopause.Advances in both synthetic and natural preparations allowed for more personalized treatmentapproaches. When selecting estrogen-progestin therapies, it is essential to consider their impacton bone health and remodelling. OBJECTIVE: This narrative review examines the effects of variousestrogen-progestin regimens on bone metabolism across the female lifespan, focusing on mechanisms of action, safety profiles, and clinical applications. Here we show that combined oralcontraceptives (COCs) are generally safe for bone mineral density (BMD) in adult women;however, caution is advised in adolescence, especially with very low-dose estrogen formulations.In hypogonadal women, postmenopausal hormone replacement therapy (HRT) is key forosteoporosis prevention. Physiological regimens, preferably transdermal estrogen at doseshigher than those used in typical postmenopausal therapy, may offer better bone protection.Additionally, oral gonadotropin-releasing hormone receptor (GnRH-R) antagonists combinedwith add-back therapy represent a novel long-term option for managing uterine fibroids andendometriosis without compromising BMD. In postmenopausal women, both HRT and selectiveestrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health. MAIN RESULTS & IMPLICATIONS: Optimizing therapeutic strategies to balance efficacy and safety, iscritical to ensuring personalized care that preserves bone health and enhances quality of lifeacross a woman's lifespan.

Fields of Study & Subjects

Bone health and osteoporosis research Menopause: Health Impacts and Treatments Estrogen and related hormone effects

Publication details

Journal / source
Journal of Endocrinological Investigation
Publisher
Springer Science and Business Media LLC
Volume
49
Issue
10
Pages
2611-2626
Publication date
18 February 2026
Language
EN